Healthy Extracts Expects 2024 Net Revenue Up 24%, Driving Positive Cash Flow
Healthy Extracts (OTCQB:HYEX) expects to report record results for 2024, with net revenue projected to exceed $3.1 million, up 24% year-over-year. The company achieved positive operating cash flow, driven by an 80% growth in subscription-based recurring revenue through its 'Subscribe & Save' program.
The company maintained a top-three ranking in its Amazon category, demonstrating strong performance in direct-to-consumer channels and momentum with retail partners. For 2025, HYEX plans to launch new products in Q1, including an on-the-go hydration product, a sugar blocker, and a heart health formulation targeting 40 million statin users in the U.S.
The company enters 2025 with solid cash flow, manageable debt, and a favorable capitalization structure, anticipating another year of record growth supported by M&A opportunities.
Healthy Extracts (OTCQB:HYEX) prevede di riportare risultati record per il 2024, con ricavi netti previsti superiori a 3,1 milioni di dollari, con un incremento del 24% rispetto all'anno precedente. L'azienda ha registrato un flusso di cassa operativo positivo, sostenuto da una crescita dell'80% nei ricavi ricorrenti basati su abbonamenti attraverso il suo programma 'Subscribe & Save'.
L'azienda ha mantenuto una posizione tra le prime tre nella sua categoria su Amazon, dimostrando forti performance nei canali diretti al consumatore e slancio con i partner retail. Per il 2025, HYEX pianifica il lancio di nuovi prodotti nel primo trimestre, tra cui un prodotto per l’idratazione on-the-go, un bloccante di zucchero e una formulazione per la salute del cuore mirata a 40 milioni di utenti di statine negli Stati Uniti.
L’azienda entra nel 2025 con un solido flusso di cassa, debito gestibile e una struttura di capitalizzazione favorevole, prevedendo un altro anno di crescita record supportato da opportunità di M&A.
Healthy Extracts (OTCQB:HYEX) espera informar resultados récord para 2024, con ingresos netos proyectados que superan los $3.1 millones, un aumento del 24% interanual. La compañía logró un flujo de caja operativo positivo, impulsado por un crecimiento del 80% en los ingresos recurrentes basados en suscripciones a través de su programa 'Subscribe & Save'.
La compañía mantuvo un ranking entre los tres primeros en su categoría de Amazon, demostrando un fuerte desempeño en canales directos al consumidor y un buen impulso con socios minoristas. Para 2025, HYEX planea lanzar nuevos productos en el primer trimestre, incluyendo un producto de hidratación para llevar, un bloqueador de azúcar y una formulación para la salud del corazón dirigida a 40 millones de usuarios de estatinas en EE. UU.
La compañía entra en 2025 con un sólido flujo de caja, deuda manejable y una estructura de capitalización favorable, anticipando otro año de crecimiento récord apoyado por oportunidades de fusiones y adquisiciones.
Healthy Extracts (OTCQB:HYEX)는 2024년 기록적인 결과를 보고할 것으로 예상하며, 순수익은 310만 달러 이상으로, 전년 대비 24% 증가할 것으로 보입니다. 회사는 'Subscribe & Save' 프로그램을 통해 구독 기반의 반복 수익이 80% 성장하면서 긍정적인 운영 현금 흐름을 달성했습니다.
회사는 아마존 카테고리에서 상위 3위 안에 드는 성과를 유지하며, 소비자 직접 판매 채널에서 강력한 성과를 보이고, 소매 파트너와의 관계에서도 좋은 반응을 얻고 있습니다. 2025년에는 HYEX가 1분기에 이동 중 수분 공급 제품, 설탕 차단제 및 미국 내 4천만 명의 스타틴 사용자 대상 심장 건강 포뮬레이션을 포함한 신제품을 출시할 계획입니다.
회사는 2025년을 든든한 현금 흐름, 관리 가능한 부채, 유리한 자본 구조를 갖춘 상황으로 맞이하며, M&A 기회를 통해 또 하나의 기록적인 성장 해를 기대하고 있습니다.
Healthy Extracts (OTCQB:HYEX) prévoit de publier des résultats records pour 2024, avec des revenus nets projetés dépassant 3,1 millions de dollars, en hausse de 24 % par rapport à l'année précédente. L'entreprise a réalisé un flux de trésorerie opérationnel positif, soutenu par une croissance de 80 % des revenus récurrents basés sur des abonnements grâce à son programme 'Subscribe & Save'.
L'entreprise a maintenu une position parmi les trois premières dans sa catégorie sur Amazon, montrant une performance solide dans les canaux directs aux consommateurs et un élan avec ses partenaires de distribution. Pour 2025, HYEX prévoit de lancer de nouveaux produits au premier trimestre, y compris un produit d'hydratation à emporter, un bloqueur de sucre et une formulation pour la santé cardiaque ciblant 40 millions d'utilisateurs de statines aux États-Unis.
L'entreprise aborde 2025 avec un flux de trésorerie solide, une dette gérable et une structure de capitalisation favorable, anticipant une nouvelle année de croissance record soutenue par des opportunités de fusions et acquisitions.
Healthy Extracts (OTCQB:HYEX) erwartet für 2024 rekordverdächtige Ergebnisse, mit prognostizierten Nettoumsätzen von über 3,1 Millionen Dollar, was einem Anstieg von 24% im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte einen positiven operativen Cashflow, der durch ein 80%iges Wachstum bei den abonnementbasierten wiederkehrenden Einnahmen über sein 'Subscribe & Save'-Programm unterstützt wurde.
Das Unternehmen behielt eine Top-Drei-Platzierung in seiner Amazon-Kategorie bei, was starke Leistungen in den direkten Verbraucherkanelen und Auftrieb bei Einzelhandelspartnern zeigt. Für 2025 plant HYEX die Einführung neuer Produkte im ersten Quartal, darunter ein Produkt zur Flüssigkeitszufuhr für unterwegs, einen Zuckerblocker und eine Herzgesundheitsformulierung, die sich an 40 Millionen Statin-Nutzer in den USA richtet.
Das Unternehmen geht mit einem soliden Cashflow, beherrschbarer Verschuldung und einer vorteilhaften Kapitalstruktur ins Jahr 2025 und erwartet ein weiteres Jahr mit Rekordwachstum, unterstützt durch M&A-Möglichkeiten.
- Net revenue expected to exceed $3.1M in 2024, up 24% YoY
- Achieved positive operating cash flow
- Subscription-based recurring revenue grew 80% YoY
- Secured top-three ranking in Amazon category
- Strong cash flow position with manageable debt
- Financial results are preliminary and unaudited
- New product success in untested categories remains uncertain
Results Driven by
LAS VEGAS, NV / ACCESSWIRE / January 14, 2025 / Healthy Extracts Inc. (OTCQB:HYEX), an innovative platform for acquiring, developing, patenting, marketing and distributing plant-based nutraceuticals, expects to report record results for the year ended December 31, 2024.
For full year 2024, net revenue is expected to exceed a record
"Our anticipated record-breaking revenue and profits for the year reflects strong performance across our direct-to-consumer channels and our strengthening momentum with key retail partners," commented Healthy Extracts president, Duke Pitts.
"We believe our focus on customer retention, product quality and innovation, and strategic customer engagement continues to set us apart from the competition," added Pitts. "We have also been effective in leveraging our expertise to dominate key sales channels, like Amazon, where we see the potential to generate millions in additional annual sales with each new product launch."
Healthy Extracts' record Amazon sales in 2024 was demonstrated by its top three ranking in its category, and this resulting from its optimized sales and marketing efforts.
The company's successful "Subscribe & Save" program for both Amazon and direct-to-consumer sales boosted its recurring revenue stream, up
2025 Outlook
"As we begin the new year, we are looking forward to building upon our success in 2024 with the launch of a new series of groundbreaking products," continued Pitts. "Targeting for release during the first quarter, these new products will be specifically formulated for new high-growth categories."
These anticipated new products include a groundbreaking on-the-go hydration product; an easy-to-consume sugar blocker; and a revolutionary heart health formulation targeting the more than 40 million statin users in the U.S.
The hydration and sugar blocker represent new category entries for the company, while the new heart health product is expected to expand this most successful category for the company to new levels.
All of these products will tap the company's well-established customer base, while attracting new audiences and creating significant cross-selling opportunities.
"We enter 2025 with solid cash flow, manageable debt, and a highly favorable capitalization structure," said Pitts. "This strong position supports our outlook for another year of record growth. We also see our M&A opportunities further strengthening our positive outlook and enhancing our ability to deliver greater shareholder value."
The preliminary unaudited results provided in this press release are estimates only and subject to change without notice until the company officially reports its audited annual results in March.
About Healthy Extracts"Live Life Young Again"
Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals.
The company's subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids.
UBN's KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2024, and future periodic reports filed with the SEC. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food & Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.
BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™
Company Contact
Duke Pitts, President
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact
Investor Contact
Ronald Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email contact
SOURCE: HEALTHY EXTRACTS INC.
View the original press release on accesswire.com
FAQ
What is Healthy Extracts (HYEX) projected revenue growth for 2024?
How much did HYEX's subscription-based recurring revenue grow in 2024?
What new products is HYEX launching in Q1 2025?
What was HYEX's Amazon marketplace performance in 2024?
When will HYEX release its official audited annual results for 2024?
